Phase 2 × Completed × Lymphoma, T-Cell, Peripheral × Clear all A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Phase 2 Completed
82 enrolled 13 charts
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Phase 2 Completed
82 enrolled 20 charts
AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
Phase 2 Completed
57 enrolled
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine
Phase 2 Completed
71 enrolled
AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)
Phase 2 Completed
48 enrolled
REDIRECT
Phase 2 Completed
108 enrolled 24 charts
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Phase 2 Completed
77 enrolled 20 charts
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 2 Completed
55 enrolled 18 charts
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
Phase 2 Completed
52 enrolled 24 charts
PTCL
Phase 2 Completed
65 enrolled 16 charts
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Phase 2 Completed
38 enrolled
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Phase 2 Completed
1 enrolled 5 charts
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Phase 2 Completed
4 enrolled 11 charts
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 2 Completed
67 enrolled 13 charts
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
Phase 2 Completed
76 enrolled 10 charts
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Phase 2 Completed
34 enrolled 12 charts
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Phase 2 Completed
21 enrolled 11 charts
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 2 Completed
41 enrolled 8 charts
PTCL
Phase 2 Completed
129 enrolled 12 charts
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
Phase 2 Completed
45 enrolled 28 charts
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Phase 2 Completed
49 enrolled 11 charts
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Phase 2 Completed
131 enrolled 16 charts
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Phase 2 Completed
60 enrolled 10 charts
Allo-hNHL (FluBuCy)
Phase 2 Completed
84 enrolled
PROPEL
Phase 2 Completed
115 enrolled 11 charts
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
Phase 2 Completed
36 enrolled
FIL_GEMRO
Phase 2 Completed
20 enrolled 11 charts
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
94 enrolled 11 charts
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
77 enrolled 12 charts
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
Phase 2 Completed
60 enrolled
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Phase 2 Completed
16 enrolled 10 charts
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
Phase 2 Completed
60 enrolled
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
12 enrolled 10 charts
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
Phase 2 Completed
43 enrolled 5 charts
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Phase 2 Completed
43 enrolled 14 charts
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Completed
53 enrolled 10 charts
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase 2 Completed
131 enrolled 18 charts
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
14 enrolled 7 charts
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Phase 2 Completed
25 enrolled
CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
Phase 2 Completed
41 enrolled
PTCL-06
Phase 2 Completed
92 enrolled
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Phase 2 Completed
50 enrolled
A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT
Phase 2 Completed
166 enrolled